| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Biodegradable block copolymers for delivery of proteins and water-insoluble drugs.
|
J Control Release
|
2001
|
1.85
|
|
2
|
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
|
Anticancer Drug Des
|
2000
|
1.21
|
|
3
|
Phase I therapy trials in children with cancer.
|
J Pediatr Hematol Oncol
|
1998
|
1.19
|
|
4
|
Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response.
|
Br J Clin Pharmacol
|
2007
|
1.12
|
|
5
|
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
|
Clin Cancer Res
|
2001
|
1.08
|
|
6
|
Squalamine treatment of human tumors in nu/nu mice enhances platinum-based chemotherapies.
|
Clin Cancer Res
|
2001
|
0.93
|
|
7
|
Elevated expression of DNA ligase I in human cancers.
|
Clin Cancer Res
|
2001
|
0.87
|
|
8
|
Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model.
|
Cancer Res
|
1999
|
0.85
|
|
9
|
Water soluble 20(S)-glycinate esters of 10,11-methylenedioxycamptothecins are highly active against human breast cancer xenografts.
|
Cancer Res
|
1999
|
0.82
|
|
10
|
Pediatric phase I drug tolerance: a review and comparison of recent adult and pediatric phase I trials.
|
J Pediatr Hematol Oncol
|
1996
|
0.81
|
|
11
|
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
|
Ann Oncol
|
1999
|
0.80
|
|
12
|
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
|
J Clin Oncol
|
2000
|
0.79
|
|
13
|
Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model.
|
Eur J Cancer
|
2000
|
0.79
|
|
14
|
Exploring the mechanisms of action of FB642 at the cellular level.
|
J Cancer Res Clin Oncol
|
2001
|
0.79
|
|
15
|
A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors.
|
Med Pediatr Oncol
|
2001
|
0.77
|
|
16
|
Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
0.77
|
|
17
|
Antitumor activity of irofulven against human ovarian cancer cell lines, human tumor colony-forming units, and xenografts.
|
Int J Gynecol Cancer
|
2004
|
0.77
|
|
18
|
Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.
|
Cancer Chemother Pharmacol
|
1999
|
0.76
|
|
19
|
A new cyclosporine formulation.
|
Transplantation
|
1990
|
0.75
|